LogMAR and PRIMA Highlights in 90 Seconds

Why It Matters

A 0.2 LogMAR gain translates to meaningful daily‑living vision for AMD patients, potentially reshaping treatment standards and market dynamics in retinal prosthetics.

Key Takeaways

• LogMAR quantifies visual acuity using base‑10 logarithm scale
• Each 0.1 LogMAR increase equals loss of one eye‑chart line
• Doubling visual angle raises LogMAR by 0.3, losing three lines
• PRIMA implant restores light perception via photovoltaic microarray beneath retina
• Clinical trial shows average 0.2 LogMAR improvement, adding two chart lines

Summary

The video explains LogMAR, the logarithmic metric for visual acuity, and introduces PRIMA, a photovoltaic retinal prosthesis designed to restore central vision. LogMAR is the base‑10 logarithm of the minimum angle of resolution; a 0.1 increase corresponds to losing one line on a standard eye chart, while a doubling of visual angle adds 0.3 LogMAR, erasing three lines.

The PRIMA system consists of a micro‑array implanted beneath the central retina that converts near‑infrared light projected from camera‑equipped glasses into electrical stimulation. In an open‑label, multicenter prospective study of patients with severe vision loss from geographic atrophy due to age‑related macular degeneration, the majority achieved at least a 0.2 LogMAR gain, equivalent to reading two additional lines on the chart.

Researchers highlighted that participants could consistently read ten more letters than at baseline, underscoring the device’s functional benefit. The study, published in the New England Journal of Medicine, emphasizes the reproducibility of the visual improvement across diverse patient cohorts.

If these results scale, PRIMA could become a transformative therapy for AMD‑related blindness, opening new revenue streams for retinal‑implant manufacturers and prompting insurers to consider coverage for vision‑restoring prosthetics.

Original Description

NEJM Editorial Fellow Katerina Lin, MD, explains a clinical trial in which the photovoltaic retina implant microarray (PRIMA) system restored central vision and led to a significant improvement in visual acuity. Read the full PRIMAvera trial results at NEJM.org.

#ophthalmology #nejm